Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01504776 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

A Phase 1 study of Mantle Cell Lymphoma, sponsored by Anand Jillella.

Completed
Registry status
Phase 1
Development phase
3
Enrollment target
1
Study location

NCT01504776 is a Phase 1 study of Mantle Cell Lymphoma that has completed, run by Anand Jillella. The registered enrollment target is 3 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01504776, a Phase 1 study of Mantle Cell Lymphoma, has completed, sponsored by Anand Jillella.

COMPLETED
Registry status
Phase 1
Development phase
3 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.

Conditions Studied

Mantle Cell Lymphoma

Interventions

  • DRUG Bortezomib
  • DRUG Panobinostat

Study Locations (1)

Georgia

  • Georgia Regents University - Augusta

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2011-04
Est. Completion 2014-09
Phase Phase 1

Sponsor

Anand Jillella

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01504776

The ClinicalTrials.gov registry entry for NCT01504776 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (97% lower). The listed sponsor is Anand Jillella, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib is the first listed.

NCT01504776 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT01504776 about?

NCT01504776 is a clinical study titled "Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)". The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.

What is the current status of trial NCT01504776?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-04. Estimated completion is 2014-09.

What conditions does trial NCT01504776 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma.

What interventions are being tested in trial NCT01504776?

The interventions under investigation include: Bortezomib (DRUG), Panobinostat (DRUG).

Who is sponsoring clinical trial NCT01504776?

This trial is sponsored by Anand Jillella, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01504776 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.